• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在有和没有囊性纤维化的儿童中,管理和监测氯法齐明治疗非结核分枝杆菌感染。

Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis.

机构信息

Baylor College of Medicine, Department of Pediatrics, United States; Section of Pediatric Infectious Diseases, United States.

University of Florida, Department of Pharmacy, United States.

出版信息

J Cyst Fibros. 2022 Mar;21(2):348-352. doi: 10.1016/j.jcf.2021.08.010. Epub 2021 Sep 1.

DOI:10.1016/j.jcf.2021.08.010
PMID:34479810
Abstract

Few studies have evaluated clofazimine (CLOF) drug monitoring and safety in children. We treated 10 children, 8 with CF, for NTM infection with multiple antimicrobials, including CLOF. All had serial blood CLOF concentrations measured and were followed for adverse events. Despite CLOF dose escalation, most children with CF did not reach a target CLOF concentration. Our data suggest that children with CF may require earlier initiation of CLOF at higher doses than is currently recommended.

摘要

鲜有研究评估过氯法齐明(CLOF)的药物监测和儿童用药安全性。我们用包括氯法齐明在内的多种抗生素治疗了 10 名儿童,其中 8 名为 CF 患者,治疗非结核分枝杆菌感染。所有患者都进行了连续的血液氯法齐明浓度检测,并观察不良事件。尽管增加了氯法齐明的剂量,但大多数 CF 患儿仍未达到目标浓度。我们的数据表明,CF 患儿可能需要比目前建议的更早开始更高剂量的氯法齐明治疗。

相似文献

1
Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis.在有和没有囊性纤维化的儿童中,管理和监测氯法齐明治疗非结核分枝杆菌感染。
J Cyst Fibros. 2022 Mar;21(2):348-352. doi: 10.1016/j.jcf.2021.08.010. Epub 2021 Sep 1.
2
Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.氯法齐明治疗原发性和复发性非结核分枝杆菌感染的安全性和有效性。
Chest. 2017 Oct;152(4):800-809. doi: 10.1016/j.chest.2017.04.175. Epub 2017 May 5.
3
Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections.氯法齐明吸入混悬液用于治疗非结核分枝杆菌肺部感染的雾化治疗。
J Cyst Fibros. 2019 Sep;18(5):714-720. doi: 10.1016/j.jcf.2019.05.013. Epub 2019 May 25.
4
Nontuberculous mycobacterial infections in cystic fibrosis.囊性纤维化中的非结核分枝杆菌感染。
Clin Chest Med. 2015 Mar;36(1):101-15. doi: 10.1016/j.ccm.2014.11.003.
5
Treating nontuberculous mycobacteria in children with cystic fibrosis: a multicentre retrospective study.囊性纤维化患儿中非结核分枝杆菌的治疗:一项多中心回顾性研究。
Arch Dis Child. 2022 May;107(5):479-485. doi: 10.1136/archdischild-2021-322177. Epub 2021 Nov 5.
6
Challenging scenarios in nontuberculous mycobacterial infection in cystic fibrosis.囊性纤维化中非结核分枝杆菌感染的挑战性情况。
Pediatr Pulmonol. 2020 Feb;55(2):521-525. doi: 10.1002/ppul.24604. Epub 2019 Dec 10.
7
Prevalence and importance of non-tuberculous mycobacteria in adult patients with cystic fibrosis in a hospital in Madrid.马德里一家医院成人囊性纤维化患者中非结核分枝杆菌的流行情况及重要性。
Enferm Infecc Microbiol Clin (Engl Ed). 2020 Aug-Sep;38(7):323-326. doi: 10.1016/j.eimc.2019.09.007. Epub 2019 Nov 16.
8
High incidence of non-tuberculous mycobacteria-positive cultures among adolescent with cystic fibrosis.青少年囊性纤维化患者分枝杆菌阳性培养的发生率较高。
J Cyst Fibros. 2017 Sep;16(5):579-584. doi: 10.1016/j.jcf.2017.01.017. Epub 2017 Feb 12.
9
Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward.囊性纤维化中的非结核分枝杆菌:最新进展与未来方向
Pediatr Pulmonol. 2017 Nov;52(S48):S29-S36. doi: 10.1002/ppul.23825. Epub 2017 Sep 7.
10
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.囊性纤维化中非结核分枝杆菌药物治疗的临床药代动力学和药效学考虑因素。
Clin Pharmacokinet. 2021 Sep;60(9):1081-1102. doi: 10.1007/s40262-021-01010-4. Epub 2021 May 13.

引用本文的文献

1
Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.囊性纤维化患者非结核分枝杆菌肺部感染的抗生素治疗
Cochrane Database Syst Rev. 2025 Mar 27;3(3):CD016039. doi: 10.1002/14651858.CD016039.
2
Multidrug-resistant tuberculosis in children: A practical update on epidemiology, diagnosis, treatment and prevention.儿童耐多药结核病:关于流行病学、诊断、治疗及预防的实用最新进展
J Clin Tuberc Other Mycobact Dis. 2024 May 1;36:100449. doi: 10.1016/j.jctube.2024.100449. eCollection 2024 Aug.
3
Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis.
治疗药物监测在耐多药结核病治疗中的作用
J Clin Tuberc Other Mycobact Dis. 2024 Apr 24;36:100444. doi: 10.1016/j.jctube.2024.100444. eCollection 2024 Aug.
4
Aryl hydrocarbon receptor is a tumor promoter in -amplified neuroblastoma cells through suppression of differentiation.芳烃受体通过抑制分化,在扩增的神经母细胞瘤细胞中是一种肿瘤促进因子。
iScience. 2023 Oct 21;26(11):108303. doi: 10.1016/j.isci.2023.108303. eCollection 2023 Nov 17.
5
Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs.非结核分枝杆菌病:新型候选药物和再利用药物研发的进展与突破。
Front Cell Infect Microbiol. 2023 Oct 2;13:1243457. doi: 10.3389/fcimb.2023.1243457. eCollection 2023.